European Investment Bank

Sidekick is a patient-centric digital care platform designed to manage and prevent chronic and lifestyle-related conditions. It offers a scalable solution that enhances healthcare by developing digital health products aimed at empowering patients and digitizing healthcare processes. The platform combines an evidence-based clinical approach with elements of behavioral economics and gamification, creating a more engaging healthcare experience. Sidekick's integrated platform supports multi-chronic condition management and personalized care, facilitating connections between users and clinicians while providing valuable data insights. The company collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve health outcomes.

Norlase is a developing global ophthalmic medical device company focused on creating innovative laser solutions for the treatment of retinal and glaucoma diseases. The company has introduced advanced ophthalmic laser technologies, including ECHO and LEAF. ECHO is notable for being the world's first truly portable pattern laser, featuring battery power and a wireless user interface with voice control, which enhances its portability and flexibility during treatments. LEAF is an ultra-compact green laser photocoagulator that conveniently attaches to existing slit lamps, thus simplifying laser procedures by eliminating the need for external fibers or extra equipment. Norlase aims to provide affordable access to powerful laser technologies for effective patient care.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

TactoTek specializes in injection-molded structural electronics (IMSE®), focusing on the development and licensing of technologies that enable the integration of circuits and components directly into plastic parts. This innovation allows for the transformation of traditional structures into smart, interactive surfaces, catering to sectors such as automotive, aviation, connected home, industrial control, and medical applications. TactoTek's intellectual property portfolio includes over 280 patents and extensive expertise acquired through years of research and development. The company partners with global manufacturers to implement reliable and standardized production methods for curved and conformal electronics, thereby facilitating cost-effective and scalable design solutions that enhance user experiences while promoting sustainability.

WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Protembis GmbH, founded in 2017 and based in Aachen, Germany, specializes in the manufacture of surgical equipment aimed at enhancing the safety of transcatheter aortic valve replacement (TAVR) procedures. The company has developed the ProtEmbo System, an intra-aortic filter device designed to mitigate the risk of cerebrovascular events during TAVR by deflecting embolic material away from the cerebral circulation. This innovation addresses a significant complication associated with TAVR, which has become a preferred treatment for patients with valvular heart disease, particularly as the procedure is increasingly performed on younger and lower-risk individuals. By minimizing the risk of brain injury, Protembis aims to improve patient outcomes and reduce healthcare costs related to surgical complications.

AT&S is a Europe-based printed circuit board manufacturer focused on high-end printed circuit board technology. Depending on technological and economic requirements, the company offers the widest possible range of printed circuit boards specially tailored to customers’ needs such as double-sided plated-through, multi-layer, high density interconnection and laser-drilled, insulated metallic substrate, flexible, rigid-flex, and semi-flexible. The core businesses of AT&S are mobile devices and substrates, automotive, industrial, medical, aviation, and advanced packaging. It has approximately 7,300 employees, of which around 1,200 are in Austria. In the 2013 and 2014 financial year AT&S’s sales revenues totaled 590 million euros, and earnings before interest and tax were 53.9 million euros. AT&S is headquartered in Leoben, Austria.

Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Demant is the only company in the world that covers all areas of hearing healthcare, from hearing devices and hearing implants to diagnostic instruments and professional hearing care, and we harvest significant synergies from this unique position and expect to create new opportunities in the years to come.

SpinDiag GmbH is a medical technology company based in Freiburg, Germany, focused on developing automated point-of-care systems for the rapid and reliable detection of infectious diseases. Founded in 2016, the company has created a centrifugal-microfluidic test system that allows healthcare providers to screen for the 25 most common antibiotic resistances directly from patient samples upon hospital admission. This innovative system helps prevent the spread of drug-resistant bacteria by enabling the immediate isolation of infected patients. SpinDiag's first product is an automated SARS-CoV-2 test that provides laboratory-grade PCR results directly from standard patient swab samples, streamlining the workflow for nurses and integrating seamlessly into clinical practice. The fully automated system eliminates the need for manual pipetting, thereby minimizing the risk of infection and enhancing the efficiency of pathogen detection in hospital settings.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

TRUMPF is a high-technology company based in Ditzingen, Germany, specializing in the manufacturing of machine tools, industrial lasers, and medical technologies. Renowned as a leader in flexible sheet metal processing, TRUMPF is committed to advancing digital connectivity within the manufacturing industry through innovative consulting, platforms, and software solutions. As a family-owned enterprise, it emphasizes long-term thinking and sustainable growth, bolstering its reputation for continuous innovation. TRUMPF Venture, the company's corporate venture capital arm, aims to foster innovation by investing globally in early-stage startups that align with TRUMPF's core business areas, including photonics, manufacturing technology, and industrial software systems. The venture arm seeks companies with a strategic fit, strong management teams, and potential for significant market differentiation, providing these startups access to TRUMPF's extensive network and expertise to enhance their scalability and success.

eCential Robotics specializes in enhancing minimally invasive surgical procedures through advanced imaging technology. The company has developed a system that combines fluoroscopy, surgical navigation, and robotics to improve treatment outcomes across various medical indications. This integrated operating system offers high-definition imaging and real-time navigation, which aids surgeons in performing complex orthopedic and trauma surgeries. By enabling day surgery practices, eCential Robotics provides significant benefits to patients and healthcare providers alike, including reduced radiation exposure, increased safety, and improved accuracy during operations.

Essity is a health and hygiene company headquartered in Stockholm, Sweden, that specializes in the manufacture and sale of personal care and baby products. Established in June 2017 as a spin-off from Svenska Cellulosa, Essity's product range includes feminine care, baby care, toilet paper, facial tissue, wet wipes, hand soap, hand sanitizers, and tissue dispensers aimed at institutional customers. Additionally, the company provides medical solutions such as wound care, orthopedics, and compression therapy, which contribute approximately 7% of its net sales. Essity operates in 150 markets worldwide, with around 60% of its revenue generated in Europe.

miDiagnostics is a Belgian company focused on creating innovative, chip-based technology for self-administered blood analysis. The company is developing a new generation of disposable tests that require only small drops of blood, allowing for the detection of various biomarkers, including cells, proteins, nucleic acids, and small molecules. Their technology integrates a nanofluidic processor on a chip with a compact reader, facilitating lab-quality diagnostics from easy-to-access samples like finger-prick blood or nasal swabs. This approach enables both patients and clinicians to conduct rapid diagnostics conveniently and efficiently, regardless of location.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

Scope Fluidics S.A., founded in 2010 in Warsaw, Poland, specializes in the development and manufacturing of innovative diagnostic devices that leverage microfluidic technology. The company creates disposable systems designed for the efficient collection of micro-samples of blood and the storage of reagents for various diagnostic markers. It aims to address global health challenges by integrating insights from academia and medical practices to produce high-potential solutions. Scope Fluidics operates through two special purpose vehicles, Curiosity Diagnostics and Bacteromic, which focus on specific projects in diagnostics and med tech. The organization fosters collaboration among physicians, engineers, and scientists to develop effective responses to market needs and social requirements in healthcare.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

Ottobock is a designer and manufacturer of prosthetic limbs dedicated to enhancing the mobility and quality of life for individuals with disabilities. The company focuses on innovative solutions, offering products such as a computerized knee that adapts its resistance to accommodate various walking gaits, and a fully articulated robotic hand prosthesis. These advancements enable users to overcome challenges associated with their disabilities, promoting independence and active lifestyles. Driven by a commitment to innovation and the desire to provide optimal support for those in need, Ottobock strives to improve the overall well-being of its customers.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

Indivumed was founded in Hamburg, Germany in 2002 with one main driver – the individualization of cancer therapy through the generation, characterization, and analysis of biologic samples from human cancer patients. Since then, the company has expanded globally, with a subsidiary in the USA, partnerships with leading cancer clinics in Europe, the US and Asia and more than 50 oncology practices located in Germany, and, finally, more than 100 biopharma industry partners – and a global reputation for product and service quality.

NewIcon Oy is a health technology company established in 2007, specializing in pharmacy automation systems. As a market leader in Finland, the company has successfully implemented its automated medication dispensing solutions in over 100 pharmacies and hospitals across multiple countries, including Denmark, Russia, Israel, Iran, and China. With a workforce of approximately 70 employees, NewIcon Oy generates a turnover exceeding € 7 million. The company is committed to quality, operating under a certified ISO 9001 quality management system, and focuses on using robotics and advanced software to enhance the efficiency and safety of medication distribution, allowing healthcare providers to prioritize patient care.